[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Sentiment: XXX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XXX%
1 Month: XXX% no change
1-Year High: XXX% on 2025-09-12
1-Year Low: XXX% on 2025-09-12
Most Supportive Themes
- Positive Analyst Ratings and Price Targets: (40%) JPMorgan and Barclays initiated coverage with positive ratings and high price targets, indicating strong potential for IDYA.
- Strong Potential in Precision Oncology: (30%) The company's focus on precision oncology, particularly with upcoming IDE849 updates, is generating positive sentiment.
- Positive Clinical Data and Catalysts: (20%) Mentions of positive clinical updates and upcoming catalysts, such as darovasertib data, are driving optimism.
Most Critical Themes
- Concerns about Data Translatability: (10%) Some posts express concern about the translatability of Chinese data to Western patients, impacting sentiment.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XX | XX% | XX | XX% | X | X% |
| Total | XX | XX% | XX | XX% | X | X% |